https://www.businesswire.com/news/home/20201221005006/en/Regenacy-Announces-the-Formation-of-a-Joint-Venture-with-3E-Bioventures-to-Develop-Ricolinostat-in-China-and-the-Start-of-a-U.S.-Phase-2-Study-in-Painful-Diabetic-Peripheral-Neuropathy
Regenacy Announces the Formation of a Joint Venture with 3E Bioventures to Develop Ricolinostat in...
Regenacy announces formation of joint venture company Beijing 3E-Regenacy with 3E Bioventures and start of Phase 2 study of ricolinostat for DPN